A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Peripheral T-cell Lymphoma (PTCL). Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Center list to be confirmed — check the primary protocol.
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This real-world study aims to evaluate the safety and efficacy of golidocitinib-based treatment regimens in patients with peripheral T-cell lymphoma (PTCL), without intervention in the selection of therapeutic strategies. A total of 1,000 PTCL patients are planned to be enrolled. After screening, eligible participants meeting the inclusion and exclusion criteria will be assigned to one of three predefined cohorts: Cohort 1: Treatment-naïve patients with PTCL or NK/T-cell lymphoma. Cohort 2: Patients receiving maintenance therapy following remission after first-line induction treatment for PTCL. Cohort 3: Patients with relapsed or refractory PTCL or relapsed/refractory NK/T-cell lymphoma. There is no cap on the number of participants in each cohort.
Primary outcome measures
- Objective Response Rate [Time frame: up to 24 weeks after enrollment]
- Safety such as adverse events [Time frame: up to 4 weeks after the last dose]
Secondary outcome measures (3)
- Duration of Response [Time frame: Baseline up to data cut-off(up to approximately 3 years)]
- Progression-free survival [Time frame: Baseline up to data cut-off(up to approximately 3 years)]
- Overall survival [Time frame: Baseline up to data cut-off(up to approximately 3 years)]
Eligibility criteria
Inclusion criteria
- Voluntarily sign and acknowledge understanding of the Informed Consent Form
- Clinically confirmed diagnosis of peripheral T-cell lymphoma
- Inclusion of PTCL patients who initiated a Golidocitinib-based treatment regimen within the past 3 months
- Compliance with clinical management and provision of disease-related historical medical information required for the study, including but not limited to medical records, treatment history, and prior/prescribed therapeutic regimens
Exclusion criteria
- Poor patient adherence
- Investigator-deemed ineligibility for enrollment
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
Center list to be confirmed — check the primary protocol.
Identifiers
NCT: NCT06963632 · golidocitinib-based treatment